Megan Kirk Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 550 Springfield Ave, Berkeley Heights, NJ 07922 Phone: 908-768-2333 |
Christina Louise Gray, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Hillside Ave, Berkeley Heights, NJ 07922 Phone: 917-882-3848 |
Hand Specialty Services, Llc Occupational Therapist - Hand Medicare: Not Enrolled in Medicare Practice Location: 230 Sherman Ave, Suite 5, Berkeley Heights, NJ 07922 Phone: 908-316-2478 Fax: 908-372-4351 |
Mrs. Saroj Hemant Vaidya, OTR , CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 230 Sherman Ave, Suite 5, Berkeley Heights, NJ 07922 Phone: 908-316-2478 Fax: 908-372-4351 |
Cali Mae Clarke Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 550 Springfield Ave, Berkeley Heights, NJ 07922 Phone: 908-768-2333 |
Rethink Speech And Ot Services Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 54 Pine Grove Rd, Berkeley Heights, NJ 07922 Phone: 646-675-7925 |
Carol Martino, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922 Phone: 908-273-4300 Fax: 908-790-6524 |
News Archive
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Palex Medical S.A., one of Spain's leading distributors of medical device and diagnostic products to hospitals, today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready™ MRSA assay in Spain.
The President's caution, and his concern about business, can be seen in the way he dealt with major interest groups. ... His health-insurance bill was crafted by building support from a delicate alliance of interest groups, and Obama personally guided the effort.
IMRIS Inc. ("IMRIS" or the "Company") today announced a new organization structure designed to position the Company to continue to meet the growing global demand for IMRIS solutions.
A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study, researchers report in the July 6 issue of The Lancet.
› Verified 5 days ago